The expansion in the underpenetrated Type 2 diabetes market should support DXCM’s top-line growth going forward. In June, ...

It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology ... Its products ...

He rules continuous glucose monitors infringe second patent Abbott fails to flip third patent’s non-infringement finding Abbott Laboratories will get a new trial on damages after a federal judge found ...

3. Rebate dynamics: An accelerated shift from G6 to G7 products resulted in increased rebates paid to U.S. Pharmacy Benefit Managers (PBMs). 4. International underperformance: DexCom's performance ...

[Image courtesy of Dexcom/Oura] Dexcom (Nasdaq:DXCM) announced today that it entered into a strategic partnership with Oura, maker of leading smart ring technology. The partnership aims to help people ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.